The Science Behind Heart & Cardiovascular Supplements

Therapeutic dose: 2,000–4,000 mg/day EPA+DHA (cardioprotective doses)

See ranked Omega-3 (EPA/DHA) products→

• REDUCE-IT trial (2019, 8,179 patients) found 4g/day icosapent ethyl (pure EPA) reduced major cardiovascular events by 25% vs placebo in statin-treated patients with elevated triglycerides.PubMed ↗
• VITAL trial (2019, 25,871 participants) found 1g/day omega-3 did not significantly reduce major cardiovascular events in the general population, but did reduce MI by 28% and showed greater benefit in those with low fish intake.PubMed ↗
• 2021 meta-analysis of 38 RCTs (149,051 participants) found marine omega-3 supplementation was associated with reduced risk of MI, CHD death, total CHD, and CVD death in a dose-response manner — higher doses conferred greater benefit.PubMed ↗
• Dose matters: 1g/day (VITAL-level) shows modest benefit; 2–4g/day (REDUCE-IT level) shows substantial triglyceride reduction (20–45%) and cardiovascular risk reduction. EPA-only formulations may outperform EPA+DHA combinations.
• AHA recommends 2–4g/day EPA+DHA for triglyceride lowering. The FDA approved icosapent ethyl (Vascepa) specifically for cardiovascular risk reduction.

Therapeutic dose: 100–300 mg/day (ubiquinol form preferred)

See ranked Coenzyme Q10 (CoQ10) products→

• Q-SYMBIO trial (2014, 420 patients with chronic heart failure) found CoQ10 100mg 3x/day for 2 years reduced major adverse cardiovascular events by 43% and all-cause mortality by 42%.PubMed ↗
• 2018 meta-analysis of 14 RCTs found CoQ10 supplementation significantly reduced all-cause mortality in heart failure patients (RR 0.69).PubMed ↗
• 2018 meta-analysis of 12 RCTs found CoQ10 significantly reduced systolic blood pressure by ~4 mmHg, though effect on diastolic BP was not significant.PubMed ↗
• Statin drugs deplete CoQ10. CoQ10 supplementation at 100–200 mg/day may reduce statin-associated muscle symptoms, though trial results are mixed.
• Ubiquinol form has ~2x the bioavailability of ubiquinone. Absorption is fat-dependent — take with a fat-containing meal.

Therapeutic dose: 7–10 g/day (soluble fiber)

See ranked Psyllium Husk products→

• 2018 meta-analysis of 28 RCTs found psyllium (average 10.2 g/day) significantly reduced LDL cholesterol by 0.33 mmol/L (13 mg/dL), total cholesterol, and apoB — with greater effects in hypercholesterolemic individuals.PubMed ↗
• FDA has approved a health claim since 1998: diets containing soluble fiber from psyllium husk (at least 7g/day) may reduce the risk of coronary heart disease.
• 2020 systematic review confirmed psyllium lowers LDL by 6–24% depending on baseline levels. Effect is additive to statins — patients on statins who add psyllium get further LDL reduction.PubMed ↗
• Also significantly lowers postprandial glucose and improves glycemic control. Acts via bile acid binding and gut microbiome modulation.

Therapeutic dose: 600–1,200 mg/day aged garlic extract (or 2–5 g/day fresh equivalent)

See ranked Garlic Extract (Aged) products→

• 2020 meta-analysis of 12 RCTs (553 hypertensive patients) found aged garlic extract significantly reduced systolic BP by ~8.3 mmHg and diastolic BP by ~5.5 mmHg.PubMed ↗
• 2016 meta-analysis of 39 RCTs found garlic supplementation reduced total cholesterol by ~17 mg/dL and LDL cholesterol. Effect was most pronounced when taken for >2 months.PubMed ↗
• Aged garlic extract (Kyolic) is the most studied form. Allicin-based preparations are unstable and degrade rapidly. S-allylcysteine in aged garlic is the primary bioactive compound.
• Blood pressure-lowering effect is comparable to a first-line antihypertensive in some trials. Most effective in hypertensive individuals — modest effect in normotensive populations.

Therapeutic dose: 200–400 mg/day elemental magnesium

See ranked Magnesium products→

• 2016 meta-analysis of 34 RCTs (2,028 participants) found magnesium supplementation (mean 368 mg/day) significantly reduced systolic BP by 2.0 mmHg and diastolic BP by 1.8 mmHg.PubMed ↗
• Magnesium deficiency affects ~50% of US adults and is associated with increased risk of hypertension, arrhythmias, and atherosclerosis. Supplementation may primarily benefit those with inadequate intake.
• Blood pressure effect is modest in the general population. More pronounced benefits are seen in deficient individuals. Magnesium also improves endothelial function and reduces arterial stiffness.

Therapeutic dose: 900–1,500 mg/day (divided doses)

• 2015 meta-analysis of 27 RCTs (2,569 patients) found berberine significantly reduced total cholesterol, LDL, and triglycerides, with effects comparable to moderate-potency statins in some trials.PubMed ↗
• 2021 meta-analysis found berberine reduced LDL cholesterol by 0.65 mmol/L and triglycerides by 0.39 mmol/L. Also significantly reduced fasting glucose and HbA1c.PubMed ↗
• Mechanisms include AMPK activation, LDLR upregulation (same pathway as statins via PCSK9 inhibition), and gut microbiome modulation. Short half-life requires dosing 2–3x/day.
• Limitation: most RCTs are from Chinese populations. Gastrointestinal side effects (diarrhea, constipation) are common at >1,500 mg/day. Drug interactions with CYP3A4 substrates.

Therapeutic dose: 1,500–2,000 mg/day (extended-release)

See ranked Niacin (Vitamin B3) products→

• Niacin is the most effective agent for raising HDL cholesterol (15–35% increase) and also lowers LDL (5–25%) and triglycerides (20–50%) at pharmacological doses.
• AIM-HIGH trial (2011, 3,414 patients) and HPS2-THRIVE trial (2014, 25,673 patients) found niacin added to statin therapy did NOT reduce cardiovascular events — despite improving lipid panels.PubMed ↗
• These disappointing outcome trials led most cardiologists to abandon niacin as a cardiovascular therapy. The disconnect between lipid improvements and clinical outcomes remains poorly understood.
• Flushing is the primary side effect. Extended-release forms reduce flushing but carry hepatotoxicity risk at high doses. No-flush niacin (inositol hexanicotinate) has minimal evidence for lipid effects.

Therapeutic dose: 90–200 mcg/day (as MK-7)

• 3-year RCT (244 postmenopausal women) found MK-7 180 mcg/day improved arterial stiffness and reduced age-related decline in carotid distensibility — a marker of cardiovascular risk.PubMed ↗
• Rotterdam Study (observational, 4,807 participants) found high vitamin K2 intake was associated with 50% lower risk of coronary artery calcification and 50% lower cardiovascular mortality over 7–10 years.PubMed ↗
• Mechanism: activates matrix Gla protein (MGP), the most potent inhibitor of arterial calcification. Without sufficient K2, calcium deposits in arterial walls instead of being directed to bone.

Therapeutic dose: 1,000–4,000 IU/day (25–100 mcg)

See ranked Vitamin D products→

• VITAL trial (2019, 25,871 participants) found vitamin D 2,000 IU/day did not significantly reduce major cardiovascular events in the general population.PubMed ↗
• Meta-analysis of observational studies consistently shows 25(OH)D levels <20 ng/mL are associated with significantly increased cardiovascular risk. But supplementation in sufficient individuals does not reduce risk.
• D-Health trial (2022, 21,315 participants) found no cardiovascular benefit from monthly high-dose vitamin D supplementation over 5 years.PubMed ↗
• Current evidence suggests vitamin D supplementation corrects deficiency-related cardiovascular risk but does not provide additional cardiovascular protection in replete individuals. Focus on achieving sufficiency (>30 ng/mL).

Therapeutic dose: 1,000–3,000 mg/day

See ranked Taurine products→

• 2018 meta-analysis of 7 RCTs found taurine supplementation (1,000–6,000 mg/day) significantly reduced systolic BP by 3.1 mmHg — comparable to magnesium.PubMed ↗
• 2023 observational study in Science found taurine deficiency was associated with aging-related diseases and that taurine supplementation extended lifespan in animal models. Human cardiovascular data is still developing.PubMed ↗
• Mechanism: antioxidant, osmoregulator, modulates calcium signaling in cardiomyocytes. Heart has the highest taurine concentration of any organ. Depleted by alcohol and aging.

Therapeutic dose: 3,000–6,000 mg/day

See ranked L-Citrulline products→

• 2019 meta-analysis of 10 RCTs found L-citrulline supplementation significantly reduced systolic BP by 4.1 mmHg, with a stronger effect in hypertensive adults.PubMed ↗
• Citrulline is more effective than L-arginine at raising plasma arginine and nitric oxide levels — citrulline bypasses first-pass metabolism in the liver, whereas arginine is partially degraded by arginase.
• Also improves exercise capacity and reduces arterial stiffness. Citrulline malate form is preferred for athletic performance, but pure L-citrulline is equivalent for cardiovascular endpoints.

Therapeutic dose: 3,000–6,000 mg/day

See ranked L-Arginine products→

• 2011 meta-analysis of 11 RCTs found L-arginine reduced systolic BP by 5.4 mmHg and diastolic BP by 2.7 mmHg, but trial quality was low and durations were short.PubMed ↗
• Largely supplanted by L-citrulline in clinical practice. Oral arginine has high first-pass metabolism — approximately 40% is degraded by gut arginase before reaching systemic circulation.
• Caution: the 2006 VINTAGE MI trial was stopped early because L-arginine supplementation post-MI was associated with increased mortality. Contraindicated after heart attack.PubMed ↗

Therapeutic dose: 2,000–4,000 FU/day (100–200 mg)

See ranked Nattokinase products→

• 2017 RCT (82 patients) found 6,000 FU/day nattokinase for 26 weeks significantly reduced systolic and diastolic blood pressure. Mechanism may involve ACE inhibition and fibrinolysis.PubMed ↗
• Demonstrates potent fibrinolytic activity in vitro and in animal models — degrades fibrin clots similarly to plasmin. But no large RCTs have tested clinical endpoints (stroke, MI, DVT prevention).
• Safety concern: theoretical risk of bleeding, especially when combined with anticoagulants (warfarin, apixaban). No long-term safety data in humans.

Therapeutic dose: 4–12 mg/day (natural, from Haematococcus pluvialis)

• 2011 meta-analysis of 7 small RCTs found astaxanthin reduced CRP and MDA (oxidative stress markers) but did not significantly affect blood lipids or blood pressure.
• 2018 RCT (32 overweight adults) found 12 mg/day astaxanthin for 12 weeks reduced LDL oxidation and improved HDL function — surrogate markers only.PubMed ↗
• Potent lipid-soluble antioxidant (~6,000x stronger than vitamin C in singlet oxygen quenching). But antioxidant supplement trials have generally failed to translate in vitro potency into cardiovascular benefit.

Therapeutic dose: 500–1,500 mg/day (standard) or 80–200 mg (enhanced bioavailability forms)

See ranked Curcumin (Turmeric Extract) products→

• 2017 meta-analysis of 7 RCTs found curcumin significantly reduced CRP, TNF-alpha, and IL-6, but studies were short-term and did not measure cardiovascular events.PubMed ↗
• 2012 RCT (121 CABG patients) found curcumin 4g/day reduced in-hospital MI by 65% — intriguing but never replicated in a larger trial.PubMed ↗
• Chronic inflammation is a driver of atherosclerosis, but targeting it with curcumin for cardiovascular endpoints remains unproven. Standard curcumin has 1–2% oral bioavailability — enhanced forms are essential.

Therapeutic dose: 250–500 mg EGCG/day

See ranked Green Tea Extract (EGCG) products→

• 2015 meta-analysis of 24 RCTs found green tea catechins modestly reduced total cholesterol and LDL but did not significantly affect HDL or triglycerides.PubMed ↗
• Japanese observational studies (Ohsaki cohort, 40,530 adults) found ≥5 cups/day green tea was associated with 26% lower cardiovascular mortality. But RCTs of green tea extract have not replicated these benefits.
• Hepatotoxicity risk at high doses (>800 mg EGCG/day on empty stomach). European Food Safety Authority advises caution with concentrated green tea supplements.

Therapeutic dose: 500–1,000 mg/day supplemental (total dietary target: 2,600–3,400 mg/day)

See ranked Potassium products→

• 2017 meta-analysis found increased potassium intake (primarily dietary) reduced systolic BP by 4.5 mmHg in hypertensive adults. But most evidence is from dietary potassium, not supplements.PubMed ↗
• WHO recommends potassium intake of ≥3,510 mg/day for adults to reduce blood pressure and cardiovascular risk. Most adults consume only ~2,500 mg/day.
• Supplement doses are limited (OTC max 99 mg per pill in the US) due to hyperkalemia risk, especially in patients with renal impairment or on ACE inhibitors/ARBs. Food-based potassium is preferred.